A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
Top Cited Papers
- 10 December 2022
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 78 (4) , 684-692
Abstract
No abstract availableKeywords
Funding Information
- Arrowhead Pharmaceuticals
This publication has 21 references indexed in Scilit:
- Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver diseaseJournal of Lipid Research, 2019
- Factors Associated With Histologic Response in Adult Patients With Nonalcoholic SteatohepatitisGastroenterology, 2019
- HCV-Associated Liver Fibrosis and HSD17B13New England Journal of Medicine, 2018
- A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver DiseaseNew England Journal of Medicine, 2018
- Natural History of NAFLD/NASHCurrent Hepatology Reports, 2017
- Serum Alanine Aminotransferase as a Biomarker of Treatment Response in Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2014
- Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver diseaseProceedings of the National Academy of Sciences, 2014
- Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adultsAlimentary Pharmacology & Therapeutics, 2011
- Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase LevelsAnnals of Internal Medicine, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001